Web Research

Web Research — What the Internet Knows

The Bottom Line from the Web

The filings tell you Centene posted a $6.67B GAAP loss for FY2025 and is guiding to $3+ adjusted EPS for FY2026. The web tells you why: on July 25, 2025, Centene withdrew its full-year 2025 guidance after receiving an independent actuary (Wakely) report on Marketplace enrollment composition — destroying over $11B of shareholder value in a single trading day and triggering a wave of securities class-action lawsuits (Hagens Berman, Levi & Korsinsky, Faruqi & Faruqi, Rosen Law) alleging management knew of the deterioration before disclosure. The same management team had repurchased $3B of stock in 2024 at prices that are now ~40% above the post-crash bottom.

**The investment thesis hinges on one question the filings cannot answer:** when did London/Asher actually know the Marketplace risk-pool was breaking? The class-action complaints argue the gap between internal Wakely data and public guidance is the litigable disclosure window. Q1 2026 results (April 28, 2026) are the next data point that can confirm or refute the "snap-back" narrative.

What Matters Most

1. Securities class actions allege the July 2025 guidance withdrawal was disclosed too late

Multiple national plaintiffs' firms — Hagens Berman, Levi & Korsinsky, Faruqi & Faruqi, Rosen Law, BFA Law — filed coordinated class actions in summer 2025. The complaints allege management's optimistic 2025 guidance reaffirmed at Q1 2025 earnings (when the company actually raised revenue guidance by $4B on Feb 4, 2025) did not align with internal/Wakely actuarial data on Marketplace enrollment composition that emerged before the July 25, 2025 withdrawal. Reed Kathrein of Hagens Berman: "The allegations, if proven true, suggest a pattern where Centene's public optimism didn't align with the internal metrics, ultimately leaving investors holding the bag." Source: hagens-berman.com PR (Jul 25, 2025). Status as of April 2026: cases active, no settlement disclosed.

**Red flag:** The filings show a $6.7B impairment and a missed quarter. The web shows that what management knew, and when, is now subject to discovery. That changes the governance grade and the personal-liability exposure for officers and directors.

2. The $6.7B goodwill impairment is concentrated in legacy M&A, not the operating business

The Q3 2025 charge wiped roughly a third of Centene's accumulated goodwill from the WellCare acquisition (Jan 2020, $17.3B) and Magellan Health (Jan 2022, $2.2B; pharmacy assets divested for ~$2.8B in May 2022). Independent commentary on historyoasis.com frames Magellan as the marquee Sarah London deal; the rapid pharmacy divestiture and subsequent integration drag suggest the impairment skews toward Magellan's behavioral-health remainder rather than WellCare. The filings disclose the charge but not the segment attribution — a 10-K Item 8 review is needed to break it down.

3. The 2024 buyback was timed catastrophically — implied destruction of ~$1.5–1.8B

Centene repurchased ~$3B of stock in 2024 at prices that peaked at $64.15 before the July 2025 collapse to $25.08. The shares now trade at $41.82 (Apr 24, 2026). On a ~46–47M share repurchase basis at ~$64 average vs. the post-crash $25 trough, the timing destroyed an order of $1.8B of shareholder value — and management's confidence at the time of the buyback is the same confidence the class actions are now contesting. Source: stockanalysis.com / Reuters CNC stock feed.

**Capital allocation discipline is the third leg of the credibility trial.** Buybacks at $64 + guidance pulled at $25 + executives compensated mostly in stock = a difficult story to tell in 2026 proxy season.

4. House Judiciary Republicans subpoenaed Centene as part of an ACA fraud investigation

House Judiciary Committee Republicans subpoenaed eight ACA insurers including Centene for documents related to Obamacare subsidy administration, premium-assistance calculation, and enrollment verification. The probe runs parallel to (not duplicative of) the SEC class actions and could escalate into a DOJ referral if intent to defraud is alleged. Status, scope, and target individuals are not yet public. This adds a regulatory tail risk that is invisible in the financial filings.

5. April 6, 2026 leadership reshuffle: two new Group Presidents

Centene named Daniel Finke Group President of Markets and Commercial (Medicaid + Marketplace) and elevated Michael Carson to Group President of Medicare and Specialty. Finke is an external hire (formerly CEO of Convey Health Solutions; EVP CVS Health and President of Aetna's government/commercial business). Carson was already running WellCare/Medicare since Jan 2024. Source: investors.centene.com (Apr 6, 2026) and Healthcare Dive.

**Reads as a constructive signal:** an external hire at the GP level is the first structural change since the Marketplace blow-up. The bar is now whether Finke's 12-month operating cadence beats consensus on Marketplace MLR.

Burdick (former Centene EVP and former WellCare CEO) sits on Centene's board while serving as Chairman of LifeStance Health Group. Centene retained the Magellan behavioral-health platform after divesting Magellan Rx; the dollar value of any commercial flow between Centene's behavioral-health book and LifeStance is not disclosed in the proxy summary excerpts gathered. The 2022 proxy explicitly noted Burdick (alongside London and the late Neidorff) as having a "material relationship" with the company — which is precisely the language that warrants Item 13 review. Source: SEC DEF 14A (2022 proxy).

7. Analyst consensus is bimodal — not bearish, not bullish, polarised

Two major aggregators tell different stories: TickerNerd's 36-analyst panel shows a $44 median target (range $32–$70), while Zacks's 17-analyst panel shows an $80.88 median (range $66–$95). Recent moves: Jefferies maintained Hold and raised PT $37 → $39 (Apr 20, 2026); Barclays reaffirmed Buy (Apr 9, 2026); Truist lowered PT to $35 in Mar 2026 despite praising Medicare PDP. Bull case is "headwinds priced in"; bear case is "Q1 HBR consensus is 89.3% vs. 87.1% prior year." This dispersion is itself the signal.

8. CEO Sarah London personally bought 19,230 shares in the crisis window

On Aug 8, 2025 — two weeks after the guidance withdrawal — London made a Form 4 open-market purchase of 19,230 shares at $25.50 (~$490K personal investment). This is either a high-conviction buy from inside the storm or a planned-window purchase; the timing is the most bullish single insider signal in the dataset, in tension with the class-action narrative.

9. Q1 2026 earnings on April 28, 2026 — consensus already implies further deterioration

Consensus calls for EPS $1.85 (down 36% YoY normalized) on revenue $47.47B (+1.8%), with HBR of 89.3% vs. 87.1% prior year (220 bps deterioration). Zacks notes "Earnings ESP of 0.00% and Zacks Rank #3 suggest reduced odds of outperforming." Source: ainvest.com Q1 2026 outlook. The print lands two days after this analysis.

10. 2026 guidance ($3+ adj EPS, $186.5–190.5B revenue) is below revenue consensus

Centene's Feb 6, 2026 issuance of FY2026 adjusted EPS at "$3+" implies ~40% growth from FY2025's $2.08 base. Revenue guide of $186.5–190.5B is below the $192.47B consensus — the rare guide that implicitly walks down the top line while pointing up on margin. Source: investing.com guidance recap.

Recent News Timeline

No Results

Stock Price — One-Year Crash and Partial Recovery

The 1-year total return is -32.1%, the 5-year is -36.0%, and 2026 YTD is +1.6% (lagging the S&P 500's +4.7%). The drawdown from May 2025 high to August 2025 low was ~61%; from the low, the stock has retraced ~67%, but remains 35% below the pre-crisis peak.

Valuation Snapshot — Crisis Discount or Value Trap?

Trailing P/E

8.06

Forward P/E

14.03

EV/EBITDA

3.79

P/Sales

0.11

P/Book

1.03

No Results

The dispersion is the story. Zacks's $80.88 median and TickerNerd's $44 median imply different views of the same company by a factor of ~2x. EV/EBITDA at 3.79x ranks better than 75% of healthcare-plan peers per public ratio aggregators, but the depressed multiple reflects (1) recent EPS volatility, (2) goodwill impairment in TTM EBITDA, and (3) unresolved litigation. Trailing P/E is mathematically meaningless given the GAAP loss; forward P/E of 14x assumes the $3+ guide holds.

What the Specialists Asked

Insider Spotlight

Sarah M. London — CEO | Compensation ~$20.6M annual (6.8% salary, 93.2% equity-based per public summaries). Promoted from CTO in Mar 2022 after the Politan activist settlement removed long-tenure CEO Michael Neidorff. Made a high-profile personal Form 4 buy of 19,230 shares at $25.50 on Aug 8, 2025 (~$490K) two weeks after the guidance withdrawal — the most bullish single-insider signal in the dataset, in tension with class-action allegations.

Andrew Asher — CFO | Equity award of 173,573 shares on Mar 31, 2026 (routine annual grant). Pure equity-heavy comp continues post-crisis. No notable open-market activity surfaced.

Frederick H. Eppinger — Chairman | Director since 2023. Routine grants (~463 shares Jun 30, 2025). Direct stake ~359K shares as of Jul 2025.

Kenneth A. Burdick — Director | Former Centene EVP / former WellCare CEO; current Chairman, LifeStance Health Group; current Executive Chairman, National Veterinary Associates. 2022 proxy flags as having a "material relationship" with Centene. Routine 556-share acquisition Jun 30, 2025; direct stake ~367K shares. Item 13 related-party dollar value not disclosed in the available proxy excerpts.

Theodore Pienkos — Chief Accounting Officer / Controller | Appointed Mar 18, 2026 (replaced prior controller). CPA background. Mid-cycle controller change in a litigation-active period is a footnote worth tracking.

Daniel Finke — Group President, Markets and Commercial | Appointed Apr 6, 2026 (external hire). Formerly CEO of Convey Health Solutions; EVP CVS Health, President of Aetna government and commercial.

Michael Carson — Group President, Medicare and Specialty | Promoted Apr 6, 2026. Joined Centene/WellCare as Medicare CEO Jan 2024. Prior CEO Bright Healthcare and Harvard Pilgrim.

No Results

The London August 2025 buy is the cleanest counter-narrative to the class-action thesis: a CEO who knew the disclosure was deficient in July does not buy at the trough in August in a documented Form 4. Either the buy was 10b5-1-planned (legal cover) or it was high-conviction. Discovery in litigation may eventually surface the trading-plan documentation.

Industry Context

Sector-wide acuity shock, not Centene-specific. Molina Healthcare's cautious 2026 guidance (Feb 2026) pressured the entire managed-care peer set and corroborates the "structural post-redetermination acuity" reading rather than the "Centene execution failure" reading. The October 2022 CMS Star ratings cuts that flowed through 2024 Medicare Advantage revenue were industry-wide. Cigna ACA commentary in early 2026 also pointed to recovery from a 2025 rough patch.

Government-sponsored concentration is both moat and risk. Roughly 64% of Centene's 20M members are in Medicaid, 28% in Marketplace/exchanges, 5% in Medicare. This positioning insulates the company from commercial-employer headwinds but exposes it directly to (a) state Medicaid rate cycles, (b) ACA subsidy policy (House Judiciary subpoena risk), and (c) CMS Medicare Advantage rate notices. Three regulatory levers, three meaningful tail risks.

Peer market caps (Apr 24, 2026) for context: UnitedHealth $322B, CVS Health $99.9B, Elevance $74.9B, Cigna $72.7B, Humana $25.8B, Centene $20.6B, Molina $9.2B, Oscar Health $5.1B. CNC trades at the smallest cap among major MCOs despite ~$176B TTM revenue — a function of the post-crisis multiple compression more than any structural scale problem.

**The macro overhang to monitor:** OBBBA Medicaid work-requirement rollout schedules by state (impact 2026–2027), the CMS 2027 Medicare Advantage advance notice (final April 2026), and ACA enhanced-subsidy expiration politics (election cycle dependent). All three sit outside Centene's control.